Search

Items tagged with: Oncology

#health #oncology #medicalscience

`Overall, our work shows that oxidative stress plays a major role in centrosome overduplication, particularly in 4N cells, suggesting that supernumerary centrosomes and WGD may coexist in certain tumors.` dx.doi.org/10.1073/pnas.252207…

#cancer #oncology

#oncology #cancer

A highly sensitive blood test designed to measure circulating tumor DNA (ctDNA) in patients with early breast cancer. It successfully identifies residual disease and predicts relapse long before clinical symptoms or traditional imaging can detect it.
#Oncology #MolecularBiology #ClinicalGenetics #sflorg
sflorg.com/2026/05/ongy0526260…

Pathlight Breast Cancer Blood Test

Discover how the Pathlight blood test tracks circulating tumor DNA to detect early signs of breast cancer recurrence years before symptoms appear.
www.sflorg.com
#oncology #sflorg #molecularbiology #clinicalgenetics

#Hacking #oncology #institute #securityaffairs

The outcomes “were rather startling,” Cannon said. Nearly half of the runners had polyps, also known as adenomas, in their colons. Some of these polyps could develop into cancer, Cannon said, although many won’t. But 15 percent of the runners had large, advanced adenomas, “which are much farther along on the continuum to cancer,” he said. None had colon cancer.
#exercise #running #diet #pathology #oncology #tumorgenesis #metabolism #cancer
washingtonpost.com/wellness/20…
#running #oncology #pathology #exercise #cancer #diet #tumorgenesis #metabolism

#uk #health #oncology #medicalscience

#oncology

Collective cell movement involves cells migrating in coordination with their neighbors during biological processes such as embryonic development and wound healing. Recent discoveries reveal this coordinated movement is facilitated by the scaffolding protein ZO-1 riding waves of ERK signaling activation.
#CellBiology #MolecularBiology #Biophysics #Oncology #sflorg
sflorg.com/2026/05/cbio0525260…

ZO-1 Dynamics in Collective Cell Movement

Discover how the ZO-1 protein rides ERK activation waves to enable collective cell movement, driving vital processes from wound healing to cancer meta
www.sflorg.com
#cellbiology #oncology #sflorg #molecularbiology #biophysics

Substantial, sustained weight loss achieved through bariatric surgery significantly lowers the risk of developing and dying from cancer, particularly female-specific cancers like breast and gynecological cancers.
#MetabolicMedicine #Oncology #Endocrinology #ClinicalGenetics #sflorg
sflorg.com/2026/05/med05252601…

Bariatric Surgery & Cancer Risk Reduction

Discover how bariatric surgery lowers cancer risk in women through metabolic mechanisms and genetic factors like insulin levels and the FTO gene.
www.sflorg.com
#oncology #sflorg #metabolicmedicine #Endocrinology #clinicalgenetics

#health #oncology #medicalscience

#oncology #sflorg #molecularbiology #biochemistry #cellularpathology

#health #oncology #medicalscience

#health #oncology #medicalscience

#health #oncology #medicalscience

#health #oncology #medicalscience #fitness

Cytokine-armored CAR-T cell therapy is a novel cancer treatment that reprograms engineered T-cells to not only target cancer but also release immune-stimulating proteins. This dual action activates the body's natural immune system to strengthen the overall anti-cancer response against aggressive brain tumors like glioblastoma.
#Immunology #Oncology #CellBiology #BiomolecularEngineering #sflorg
sflorg.com/2026/05/imgy0520260…

Cytokine-Armored CAR-T Fights Glioblastoma

Discover how cytokine-armored CAR-T cell therapy utilizes IL-12 and DR-18 to recruit the immune system and eliminate aggressive glioblastoma tumors.
www.sflorg.com
#cellbiology #oncology #sflorg #immunology #biomolecularengineering

#health #oncology #medicalscience

Learn about different breast cancer types, their characteristics, symptoms, risk levels, and which forms may need urgent medical attention for better treatment outcomes.
tumblr.com/onlinecancerguide/8…

#BreastCancer #BreastCancerAwareness #CancerCare #BreastHealth #Oncology #CancerSupport #TripleNegativeBreastCancer #WomensHealth #CancerAwareness #HealthEducation

Post by @onlinecancerguide · 1 image

💬 0  🔁 0  ❤️ 0 · Breast Cancer Types and Characteristics: Which Should You Worry About · There are many forms of breast cancer, all of which have their own behaviours and ways that they respond to…
Cancer Library: Comprehensive Cancer Information (Tumblr)
#oncology #breastcancer #healtheducation #womenshealth #cancercare #breastcancerawareness #breasthealth #cancersupport #TripleNegativeBreastCancer #cancerawareness

The media in this post is not displayed to visitors. To view it, please go to the original post.
Novel mirror-image amino acid shows promise in targeting cancer cells while preserving healthy tissue, offering a more selective approach to cancer treatment. #Oncology #BioTech
#oncology #biotech

Aditxt appoints Jeff Busch as CEO of Ignite Proteomics to accelerate commercial expansion of its precision oncology platform. #Oncology #Innovation
#innovation #oncology

LIXTE Biotechnology advances PP2A inhibition strategy with LB-100 to enhance cancer treatment effectiveness by boosting tumor sensitivity and immune response. #Oncology #Biotech
#oncology #biotech

Sapu Nano to present everolimus toxicology data at SOT 2026, highlighting tissue concentration-driven effects and supporting next-gen drug delivery strategies. #Oncology #Nanomedicine
#oncology #nanomedicine

LIXTE Biotechnology advances LB-100, a PP2A inhibitor designed to enhance chemotherapy effectiveness and boost immune response in cancer treatment. #Oncology #Biotech
#oncology #biotech

Landmark proton therapy trial shows 90.9% five-year survival for oropharyngeal cancer vs. 81% with traditional radiation. Precision targeting reduces harmful exposure to healthy tissue, reshaping cancer treatment infrastructure. #ProtonTherapy #Oncology
#oncology #protontherapy

The media in this post is not displayed to visitors. To view it, please go to the original post.
Landmark study shows proton therapy achieves 90.9% five-year survival vs. 81% for traditional radiation in oropharyngeal cancer. The clinical evidence is reshaping cancer treatment infrastructure investments. #ProtonTherapy #Oncology
#oncology #protontherapy

Lixte Biotech advances precision oncology with LB-100, a first-in-class therapy enhancing cancer treatment efficacy while reducing toxicity. New partnership with Liora Technologies integrates multimodal oncology data for precision-guided care. #Oncology #Biotech
#oncology #biotech

Texas Oncology launches 'All Behind You' campaign highlighting patient journeys and compassionate care. The new platform balances medical expertise with empathy through powerful patient stories. #Healthcare #Oncology
#healthcare #oncology

The media in this post is not displayed to visitors. To view it, please go to the original post.
Lantern Pharma receives FDA clearance for STAR-001 pediatric CNS cancer trial, leveraging AI-driven RADR platform to target DNA repair mechanisms. Preclinical data shows promising survival improvements. #Biotech #Oncology
#oncology #biotech

The media in this post is not displayed to visitors. To view it, please go to the original post.
Lixte Biotech advances precision oncology with LB-100, designed to enhance cancer treatment efficacy while reducing side effects. New Liora partnership integrates multimodal data for precision-guided care. #Oncology #Biotech
#oncology #biotech

LIXTE Biotechnology doubles enrollment in LB-100 clinical trial for clear cell ovarian cancer, advancing its novel immunotherapy approach. #Oncology #Biotech
#oncology #biotech

American Shared Hospital Services extends proton therapy partnership with Orlando Health through 2033, strengthening its cancer care portfolio. Direct patient care services grew 23.7% in 2025. #Healthcare #Oncology
#healthcare #oncology

Lantern Pharma advances AI-driven oncology pipeline with Phase 2 HARMONIC trial progress and planned FDA discussions in mid-2026. Portfolio targets $15B market opportunity. #Biotech #Oncology
#oncology #biotech

LIXTE Biotechnology advances LB-100, the world's only clinical-stage PP2A inhibitor, to enhance cancer immunotherapy and chemotherapy effectiveness. #Biotech #Oncology
#oncology #biotech

The media in this post is not displayed to visitors. To view it, please go to the original post.
LIXTE Biotechnology expands LB-100 clinical trials, doubling enrollment in its ovarian cancer study. The lead compound sensitizes cancer cells to chemotherapy, addressing critical gaps in treatment for difficult malignancies. #Oncology #Biotech
#oncology #biotech

The media in this post is not displayed to visitors. To view it, please go to the original post.
LIXTE Biotechnology files 2025 10-K highlighting clinical progress on LB-100, Liora acquisition, and $11M capital raise. Advancing oncology innovation. #Biotech #Oncology
#oncology #biotech

The media in this post is not displayed to visitors. To view it, please go to the original post.
Scientists solve 50-year-old challenge in cancer drug production, engineering bacteria that generate 180% more doxorubicin. A breakthrough for treating millions of patients annually. #Oncology #Innovation
#innovation #oncology

LIXTE Biotechnology's LB-100 is the world's only clinical-stage PP2A inhibitor, enhancing cancer immunotherapy and chemotherapy response while disrupting tumor repair. #Oncology #Biotech
#oncology #biotech

Lantern Pharma showcases withZeta.ai, its groundbreaking AI platform for rare cancer drug discovery, at April 9 investor briefing. The platform has accelerated development timelines to 2-3 years. #AI #Oncology
#ai #oncology

Lantern Pharma to showcase withZeta.ai, its multi-agentic AI co-scientist for cancer drug discovery, at April 9 investor briefing. The platform accelerates development timelines and reduces costs dramatically. #AI #Oncology
#ai #oncology

Soligenix's HyBryte achieves 60% treatment success vs 20% for Valchlor in cutaneous T-cell lymphoma study, with zero treatment-related adverse events. #Biotech #Oncology
#oncology #biotech

This website uses cookies to recognize revisiting and logged in users. You accept the usage of these cookies by continue browsing this website.

⇧